ENO1 and neoplasm: Alpha-enolase autoantibodies are associated with either improved or poor tumor patient outcomes in different cancer types, suggesting a context-dependent clinical significance (Table 1; Shih et al., 2010; Tomaino et al., 2011; Pranay et al., 2013; Hsiao et al., 2015; Griggio et al., 2017).